Crandall Ryan 4

What Happened

• Ryan Crandall, Chief Commercial Officer of Marimed (MRMD), had 12,500 restricted stock units (RSUs) convert into 12,500 shares of common stock on March 7, 2026. The issuer withheld 4,332 shares to satisfy tax withholding obligations (reported as a disposition under code F) at $0.08 per share (reported total $364). The net shares remaining to Crandall from this vesting are 8,168 shares.
• The filing also records the conversion/cancellation of the derivative award (reported under code M). This is a vesting/settlement event (not an open-market buy or sell).

Key Details

• Transaction date: March 7, 2026; Form 4 filed March 9, 2026.
• Primary actions: conversion of 12,500 RSUs to common stock (code M), and withholding of 4,332 shares for taxes (code F) at $0.08/share (reported $364).
• Net shares received: 12,500 − 4,332 = 8,168 shares added to his holdings from this grant.
• Footnotes: RSUs convert 1:1 to common stock; withheld shares satisfy tax withholding; these RSUs were granted March 7, 2023 and this grant is now fully vested per the award agreement.
• Filing timeliness: No late filing noted (report covers 3/7/2026 transactions; filed 3/9/2026).

Context

• This was a vesting/settlement of RSUs (an award), not a market purchase or sale. Withholdings to cover taxes are routine and do not necessarily indicate a change in the insider’s view of the company. The filing shows the derivative award conversion and the company retaining shares to satisfy tax obligations.